Cancer treatment-related bone disease

Theresa A. Guise, Sue A. Brown

Research output: Contribution to journalReview article

28 Scopus citations

Abstract

Bone health may be impaired in many patients being treated for cancer. Primary tumors that reside in or form metastases to bone can result in compromised skeletal integrity. It has also been increasingly recognized that patients undergoing therapies for treatment of cancer are at higher risk of bone loss. These include androgen-deprivation therapy for prostate cancer and aromatase inhibitor therapy for breast cancer, among others. Hypogonadism induced by many of these cancer treatments results in bone loss and increases the risk of osteoporosis and fractures. Progress has been made in identifying the role of oral and intravenous bisphosphonates to prevent bone loss in these patients. This review discusses bone loss associated with cancer treatments, with a focus on breast cancer, prostate cancer, and survivors of childhood malignancies.

Original languageEnglish (US)
Pages (from-to)47-60
Number of pages14
JournalCritical Reviews in Eukaryotic Gene Expression
Volume19
Issue number1
StatePublished - Feb 2 2009
Externally publishedYes

Keywords

  • Bone metastases
  • Cancer
  • Hypogonadism
  • Osteoporosis
  • Treatment-related bone loss

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Fingerprint Dive into the research topics of 'Cancer treatment-related bone disease'. Together they form a unique fingerprint.

  • Cite this